Compare Stocks: SYRE, BIIB, ALNY, and ROIV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$239.56 -2.4%	$247.29	$197.81 ▼ $495.55	$32.06B	0.31	1.56 million shs	2.76 million shs
BIIB Biogen	$215.50 -1.6%	$211.00	$135.39 ▼ $225.80	$31.84B	0.17	679,223 shs	2.63 million shs
ROIV Roivant Sciences	$39.77 -0.5%	$36.18	$14.50 ▼ $42.50	$28.73B	1.12	8.86 million shs	32.20 million shs
SYRE Spyre Therapeutics	$90.25 -2.6%	$97.77	$14.51 ▼ $110.18	$7.94B	2.99	1.17 million shs	3.36 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	-3.67%	+4.47%	-13.86%	-46.97%
BIIB Biogen	0.00%	-0.76%	+0.54%	+9.62%	+48.75%
ROIV Roivant Sciences	0.00%	-2.57%	+7.95%	+26.54%	+160.27%
SYRE Spyre Therapeutics	0.00%	-0.39%	-16.27%	+2.16%	+499.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$239.56 -2.4%	$247.29	$197.81 ▼ $495.55	$32.06B	0.31	1.56 million shs	2.76 million shs
BIIB Biogen	$215.50 -1.6%	$211.00	$135.39 ▼ $225.80	$31.84B	0.17	679,223 shs	2.63 million shs
ROIV Roivant Sciences	$39.77 -0.5%	$36.18	$14.50 ▼ $42.50	$28.73B	1.12	8.86 million shs	32.20 million shs
SYRE Spyre Therapeutics	$90.25 -2.6%	$97.77	$14.51 ▼ $110.18	$7.94B	2.99	1.17 million shs	3.36 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	-3.67%	+4.47%	-13.86%	-46.97%
BIIB Biogen	0.00%	-0.76%	+0.54%	+9.62%	+48.75%
ROIV Roivant Sciences	0.00%	-2.57%	+7.95%	+26.54%	+160.27%
SYRE Spyre Therapeutics	0.00%	-0.39%	-16.27%	+2.16%	+499.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.87	Moderate Buy	$367.20	53.28% Upside
BIIB Biogen	2.58	Moderate Buy	$230.14	6.79% Upside
ROIV Roivant Sciences	2.85	Moderate Buy	$45.64	14.75% Upside
SYRE Spyre Therapeutics	2.87	Moderate Buy	$109.69	21.54% Upside

Current Analyst Ratings Breakdown

Latest SYRE, BIIB, ALNY, and ROIV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	ROIV Roivant Sciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$51.00
9/10/2026	BIIB Biogen	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$242.00
9/10/2026	BIIB Biogen	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Reduce	$165.00 ➝ $175.00
9/9/2026	ROIV Roivant Sciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $46.00
9/9/2026	ROIV Roivant Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$55.00
9/9/2026	ROIV Roivant Sciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $55.00
9/9/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$123.00
9/8/2026	ALNY Alnylam Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$230.00 ➝ $260.00
9/8/2026	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$41.00 ➝ $47.00
9/8/2026	ROIV Roivant Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $52.00
9/8/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$121.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	8.63	$2.80 per share	85.68	$5.97 per share	40.13
BIIB Biogen	$9.89B	3.22	$22.64 per share	9.52	$124.45 per share	1.73
ROIV Roivant Sciences	$8.26M	3,477.80	N/A	N/A	$7.35 per share	5.41
SYRE Spyre Therapeutics	$890K	8,917.51	N/A	N/A	$7.21 per share	12.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	44.53	24.70	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	38.14	13.38	2.38	8.32%	11.18%	6.88%	10/28/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)

Latest SYRE, BIIB, ALNY, and ROIV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
BIIB Biogen	0.39	1.87	1.26
ROIV Roivant Sciences	N/A	16.72	16.72
SYRE Spyre Therapeutics	N/A	18.53	18.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
ROIV Roivant Sciences	64.76%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
ROIV Roivant Sciences	8.80%
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable
SYRE Spyre Therapeutics	112	87.94 million	74.14 million	Optionable

SYRE, BIIB, ALNY, and ROIV Headlines

Recent News About These Companies

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Moderate Buy" by Brokerages

September 20 at 3:15 AM | americanbankingnews.com

Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

September 17 at 9:20 AM | finance.yahoo.com

Financial Contrast: Spyre Therapeutics (NASDAQ:SYRE) vs. Genmab A/S (NASDAQ:GMAB)

September 17 at 4:44 AM | americanbankingnews.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of "Moderate Buy" from Analysts

September 15, 2026 | marketbeat.com

California State Teachers Retirement System Increases Stake in Spyre Therapeutics, Inc. $SYRE

September 15, 2026 | marketbeat.com

Engineers Gate Manager LP Takes $3.42 Million Position in Spyre Therapeutics, Inc. $SYRE

September 14, 2026 | marketbeat.com

11,250 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

September 14, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Earns Outperform Rating from Wedbush

September 11, 2026 | americanbankingnews.com

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

September 10, 2026 | insidermonkey.com

Squarepoint Ops LLC Invests $12.39 Million in Spyre Therapeutics, Inc. $SYRE

September 10, 2026 | marketbeat.com

Allianz Asset Management GmbH Takes Position in Spyre Therapeutics, Inc. $SYRE

September 10, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Earns Buy Rating from BTIG Research

September 10, 2026 | americanbankingnews.com

Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

Spyre Therapeutics (SYRE) Stock Surges as Guggenheim Declares It Top Biotech Following UC Trial Results

September 9, 2026 | blockonomi.com

Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study

September 9, 2026 | zacks.com

Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE)

September 9, 2026 | marketbeat.com

Maven Securities LTD Invests $3.55 Million in Spyre Therapeutics, Inc. $SYRE

September 9, 2026 | marketbeat.com

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD ...

September 8, 2026 | markets.businessinsider.com

Spyre Therapeutics Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis

September 8, 2026 | rttnews.com

Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis

September 8, 2026 | finance.yahoo.com

Spyre Therapeutics' (SYRE) Buy Rating Reiterated at BTIG Research

September 8, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE, BIIB, ALNY, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$239.56 -5.95 (-2.42%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$239.62 +0.06 (+0.02%)

As of 09/18/2026 07:30 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$215.50 -3.55 (-1.62%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$217.00 +1.50 (+0.70%)

As of 09/18/2026 07:58 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$39.77 -0.21 (-0.53%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$40.33 +0.56 (+1.40%)

As of 09/18/2026 07:30 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Spyre Therapeutics NASDAQ:SYRE

$90.25 -2.43 (-2.62%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$90.30 +0.05 (+0.05%)

As of 09/18/2026 07:30 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SYRE, BIIB, ALNY, and ROIV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SYRE, BIIB, ALNY, and ROIV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SYRE, BIIB, ALNY, and ROIV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE, BIIB, ALNY, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Roivant Sciences NASDAQ:ROIV

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SYRE, BIIB, ALNY, and ROIV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SYRE, BIIB, ALNY, and ROIV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SYRE, BIIB, ALNY, and ROIV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE, BIIB, ALNY, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Roivant Sciences NASDAQ:ROIV

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools